MINNEAPOLIS--(BUSINESS WIRE)--Advanced Circulatory, makers of medical devices providing Intrathoracic Pressure Regulation (IPR) Therapy, will continue to work with the Food and Drug Administration (FDA) on a pathway to premarket approval (PMA) for the company’s ResQCPR System, based on recommendations from the FDA Circulatory System Devices Advisory Panel meeting on May 6. The panel considered approval of the ResQCPR System for use in the performance of CPR to increase the likelihood of survival with favorable neurologic function in adult patients with non-traumatic cardiac arrest. The panel voted unanimously that there is a reasonable assurance that the device is safe, and a majority agreed that the benefits of the ResQCPR System outweigh the risks for the device’s proposed indications. While the panel members questioned whether the data provided a reasonable assurance of effectiveness of the system based on the numerous statistical analyses presented by the company and FDA at the meeting, several explained their positive vote on risk-benefit by stating that there was a strong “signal” of effectiveness and indicated that this should be studied in a post-market setting. The panel’s discussion also focused on the complexity of performing prehospital cardiac arrest research and the need to find innovative solutions to improve survival of the nation’s third leading cause of death, cardiac arrest.
The ResQCPR System is comprised of the ResQPOD® Impedance Threshold Device (ITD) 16 and the ResQPUMP® Active Compression Decompression CPR (ACD-CPR) device. The company is seeking approval of the product combination for use in the performance of CPR to improve the likelihood of survival with favorable neurological function in adult patients with non-traumatic cardiac arrest based on the results of its pivotal clinical study, the ResQTRIAL. The ResQCPR System is Advanced Circulatory’s next IPR Therapy technology, which is intended to regulate negative intrathoracic pressure to enhance blood flow in states of poor perfusion, including cardiac arrest and shock.
Advanced Circulatory’s CEO and Director, Mike Black, commented: “We appreciate the positive feedback of the panel on the safety and risk-benefit profile of the ResQCPR System. We look forward to working with the FDA to take the panel’s recommendation into consideration and complete the next steps required to approve the ResQCPR System.”
ABOUT ResQCPR: Advanced Circulatory’s ResQCPR System consists of the ResQPOD® Impedance Threshold Device (ITD) 16 and the ResQPUMP® Active Compression Decompression CPR (ACD-CPR) device. The ResQPOD ITD regulates airflow into the lungs during CPR and is intended to enhance negative pressure in the chest, allowing more blood to be pulled back to the heart and lowering intracranial pressure. The therapy is designed to increase cardiac output, blood pressure, and blood flow to the brain and other vital organs. The ResQPUMP (CardioPump® in the European Union) ACD-CPR Device is used to perform active compression decompression (ACD) CPR, which is intended to improve conventional CPR by promoting complete and active chest wall recoil. The synergistic combination of these two devices is designed to enhance the vacuum effect in the chest, and has been shown in European clinical and pre-clinical studies to provide near-normal circulation during cardiac arrest. The ResQCPR data presented at the panel meeting demonstrate a 52% increase in survival with favorable neurological outcome (Modified Rankin Scale score of ≤ 3) at hospital discharge for patients who suffer out-of-hospital sudden cardiac arrest as compared to treatment with standard CPR.
ABOUT ADVANCED CIRCULATORY: Advanced Circulatory’s novel Intrathoracic Pressure Regulation (IPR) Therapy platform has far-reaching implications for multiple medical conditions. This non-invasive therapy is designed to increase circulation, potentially protecting the heart, brain and other vital organs when blood flow is compromised, giving rescuers, clinicians and caregivers the potential to return patients to a full life after critical medical emergencies. The company’s products are sold in over 25 countries worldwide.
Referenced studies available upon request. The generally cleared indication for the version of the ResQPOD ITD that is currently available for sale in the United States (US) is for a temporary increase in blood circulation during emergency care, hospital, clinic, and home use. The ResQPUMP and the version of the ResQPOD ITD included in the ResQCPR System is not yet approved for use in the United States. The studies referenced here are not intended to imply specific outcomes-based claims not yet cleared by the US FDA.
